We are live on ! Find out more

Outlook Therapeutics

OTLK

Market cap $164M

0.6730 USD

+0.0351

5.5%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

0.6594

-0.0136

2.02%

1 day

5.5%

5 days

5.21%

1 month

0.12%

3 months

-41.98%

6 months

91.25%

Year to date

1.97%

1 year

-35.9%

5 years

-98.61%

10 years

-99.92%

About: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Employees: 17

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40.9%

Neutral 59.1%

Negative 0%

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Access the segment here

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Video webcast now available here

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Zacks Investment Research

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

Oncobiologics Q3 Earnings Call Highlights

Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States.

Oncobiologics Q3 Earnings Call Highlights

Zacks Investment Research

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics, Inc. (OTLK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.44 per share a year ago.

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14.

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

See News Rankings

Price charts implemented using Lightweight Charts™